• First studies to assess treatment and prevention of recurrent venous thromboembolism (VTE) with dabigatran etexilate in children
• The Phase IIb/III DIVERSITY study demonstrated that the efficacy and safety profile of dabigatran was comparable to standard of care (SOC) for the treatment of children with acute VTE1
• A second Phase III study reinforced the safety profile in children with persistent VTE risk factors receiving dabigatran for prevention of recurrent VTE2
INGELHEIM, Germany-Tuesday 9 July 2019 [ AETOS Wire ]
(BUSINESS WIRE) -- Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.1,2
The data showed dabigatran to be as effective and have a comparable safety profile to the current standard of care (SOC) for the treatment of acute venou
...
Read more »